Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes
The study investigated the effect of rosiglitazone and placebo on carotid intima media thickness in patients with insulin resistance syndrome and/or type 2 diabetes.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||See Detailed Description|
- Change from baseline of the composite intima-media thickness (IMT) in the carotid artery following 52 weeks of treatment.
- Plaque occurrence & stenosis within the right carotid artery.
|Study Start Date:||May 2002|
RAS Rosiglitazone and Atherosclerosis Study: A 1 year randomised, double-blind, parallel group, placebo controlled study to evaluate the efficacy of rosiglitazone on the progression of intima-media thickness in the carotid artery in subjects with insulin resistance syndrome and/or type 2 diabetes mellitus
Please refer to this study by its ClinicalTrials.gov identifier: NCT00306644
|GSK Investigational Site|
|Malmö, Sweden, SE-205 02|
|Study Director:||GSK Clinical Trials, DM, FRCP||GlaxoSmithKline|